Compare NRP & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NRP | DFTX |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2002 | N/A |
| Metric | NRP | DFTX |
|---|---|---|
| Price | $119.49 | $18.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $40.25 |
| AVG Volume (30 Days) | 35.0K | ★ 1.3M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $216,119,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | ★ 54.66 | N/A |
| 52 Week Low | $86.83 | $14.62 |
| 52 Week High | $128.60 | $19.62 |
| Indicator | NRP | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 55.03 |
| Support Level | $100.83 | $16.26 |
| Resistance Level | $123.40 | $18.21 |
| Average True Range (ATR) | 4.12 | 0.95 |
| MACD | -0.74 | 0.04 |
| Stochastic Oscillator | 38.53 | 52.28 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).